Cortalix BV
Company Details
Status: Private
Employees: 1-10
Location:
Zernikelaan 8, Groningen, 9747 AW, NL
Type:
sample
sample
Technology:
sample
sample
sample
sample
About: Cortalix is a clinical-stage biopharmaceutical company developing imaging diagnostics and targeted radiotherapeutics based on its proprietary single domain antibodies (nanobodies) platform.
Cortalix developed a pipeline of radiopharmaceuticals that target fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis and several solid cancers with fibrotic stroma, including colon cancer and pancreatic cancer.
The Cortalix technology platform is based on the screening and selection of single domain antibodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can chelate a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach in cancer using the same single domain antibody for patient identification, targeted therapy and disease monitoring (a combined diagnostic and therapeutic in 1 molecule).
Cortalix wants to share its single domain antibodies platform, the selection of new candidate molecules from it and, if appropriate, the development of new radiopharmaceuticals with others and offers this knowledge as a service, whether or not under license.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Cortalix BV | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.